|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:LIFR-C9 (FusionGDB2 ID:HG3977TG735) |
Fusion Gene Summary for LIFR-C9 |
Fusion gene summary |
Fusion gene information | Fusion gene name: LIFR-C9 | Fusion gene ID: hg3977tg735 | Hgene | Tgene | Gene symbol | LIFR | C9 | Gene ID | 3977 | 735 |
Gene name | LIF receptor subunit alpha | complement C9 | |
Synonyms | CD118|LIF-R|SJS2|STWS|SWS | ARMD15|C9D | |
Cytomap | ('LIFR')('C9') 5p13.1 | 5p13.1 | |
Type of gene | protein-coding | protein-coding | |
Description | leukemia inhibitory factor receptorCD118 antigenLIF receptorLIF receptor alphaleukemia inhibitory factor receptor alpha | complement component C9complement component 9 | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | P42702 | P02748 | |
Ensembl transtripts involved in fusion gene | ENST00000263409, ENST00000453190, ENST00000503088, | ||
Fusion gene scores | * DoF score | 8 X 7 X 7=392 | 7 X 6 X 4=168 |
# samples | 8 | 8 | |
** MAII score | log2(8/392*10)=-2.29278174922785 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(8/168*10)=-1.0703893278914 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: LIFR [Title/Abstract] AND C9 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | LIFR(38493708)-C9(39316131), # samples:3 | ||
Anticipated loss of major functional domain due to fusion event. | LIFR-C9 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. LIFR-C9 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. LIFR-C9 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. LIFR-C9 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. LIFR-C9 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. LIFR-C9 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. LIFR-C9 seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | LIFR | GO:0008284 | positive regulation of cell proliferation | 7957045|8999038 |
Hgene | LIFR | GO:0019221 | cytokine-mediated signaling pathway | 7957045 |
Hgene | LIFR | GO:0034097 | response to cytokine | 8999038 |
Hgene | LIFR | GO:0048861 | leukemia inhibitory factor signaling pathway | 8999038|12643274 |
Hgene | LIFR | GO:0070120 | ciliary neurotrophic factor-mediated signaling pathway | 12643274 |
Tgene | C9 | GO:0001906 | cell killing | 26841934|30111885 |
Tgene | C9 | GO:0051260 | protein homooligomerization | 26841934|30111885 |
Fusion gene breakpoints across LIFR (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene breakpoints across C9 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene information * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | BRCA | TCGA-A7-A26G-01A | LIFR | chr5 | 38493708 | - | C9 | chr5 | 39316131 | - |
Top |
Fusion Gene ORF analysis for LIFR-C9 |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
5CDS-5UTR | ENST00000263409 | ENST00000509186 | LIFR | chr5 | 38493708 | - | C9 | chr5 | 39316131 | - |
5CDS-5UTR | ENST00000453190 | ENST00000509186 | LIFR | chr5 | 38493708 | - | C9 | chr5 | 39316131 | - |
5UTR-3CDS | ENST00000503088 | ENST00000263408 | LIFR | chr5 | 38493708 | - | C9 | chr5 | 39316131 | - |
5UTR-5UTR | ENST00000503088 | ENST00000509186 | LIFR | chr5 | 38493708 | - | C9 | chr5 | 39316131 | - |
Frame-shift | ENST00000453190 | ENST00000263408 | LIFR | chr5 | 38493708 | - | C9 | chr5 | 39316131 | - |
In-frame | ENST00000263409 | ENST00000263408 | LIFR | chr5 | 38493708 | - | C9 | chr5 | 39316131 | - |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000263409 | LIFR | chr5 | 38493708 | - | ENST00000263408 | C9 | chr5 | 39316131 | - | 4230 | 2228 | 163 | 2277 | 704 |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000263409 | ENST00000263408 | LIFR | chr5 | 38493708 | - | C9 | chr5 | 39316131 | - | 0.000172859 | 0.9998272 |
Top |
Fusion Genomic Features for LIFR-C9 |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
Top |
Fusion Protein Features for LIFR-C9 |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr5:38493708/chr5:39316131) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
LIFR | C9 |
FUNCTION: Signal-transducing molecule. May have a common pathway with IL6ST. The soluble form inhibits the biological activity of LIF by blocking its binding to receptors on target cells. | FUNCTION: Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells (PubMed:9634479, PubMed:9212048, PubMed:26841934). C9 is the pore-forming subunit of the MAC (PubMed:4055801, PubMed:26841934, PubMed:30111885). {ECO:0000269|PubMed:26841934, ECO:0000269|PubMed:30111885, ECO:0000269|PubMed:4055801, ECO:0000269|PubMed:9212048, ECO:0000269|PubMed:9634479}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | LIFR | chr5:38493708 | chr5:39316131 | ENST00000263409 | - | 14 | 20 | 335_434 | 688 | 1098.0 | Domain | Fibronectin type-III 2 |
Hgene | LIFR | chr5:38493708 | chr5:39316131 | ENST00000263409 | - | 14 | 20 | 435_534 | 688 | 1098.0 | Domain | Fibronectin type-III 3 |
Hgene | LIFR | chr5:38493708 | chr5:39316131 | ENST00000263409 | - | 14 | 20 | 49_138 | 688 | 1098.0 | Domain | Fibronectin type-III 1 |
Hgene | LIFR | chr5:38493708 | chr5:39316131 | ENST00000263409 | - | 14 | 20 | 538_629 | 688 | 1098.0 | Domain | Fibronectin type-III 4 |
Hgene | LIFR | chr5:38493708 | chr5:39316131 | ENST00000453190 | - | 14 | 20 | 335_434 | 688 | 1098.0 | Domain | Fibronectin type-III 2 |
Hgene | LIFR | chr5:38493708 | chr5:39316131 | ENST00000453190 | - | 14 | 20 | 435_534 | 688 | 1098.0 | Domain | Fibronectin type-III 3 |
Hgene | LIFR | chr5:38493708 | chr5:39316131 | ENST00000453190 | - | 14 | 20 | 49_138 | 688 | 1098.0 | Domain | Fibronectin type-III 1 |
Hgene | LIFR | chr5:38493708 | chr5:39316131 | ENST00000453190 | - | 14 | 20 | 538_629 | 688 | 1098.0 | Domain | Fibronectin type-III 4 |
Hgene | LIFR | chr5:38493708 | chr5:39316131 | ENST00000263409 | - | 14 | 20 | 519_523 | 688 | 1098.0 | Motif | Note=WSXWS motif |
Hgene | LIFR | chr5:38493708 | chr5:39316131 | ENST00000453190 | - | 14 | 20 | 519_523 | 688 | 1098.0 | Motif | Note=WSXWS motif |
Tgene | C9 | chr5:38493708 | chr5:39316131 | ENST00000263408 | 4 | 11 | 510_540 | 205 | 560.0 | Domain | Note=EGF-like | |
Tgene | C9 | chr5:38493708 | chr5:39316131 | ENST00000263408 | 4 | 11 | 314_330 | 205 | 560.0 | Transmembrane | Beta stranded | |
Tgene | C9 | chr5:38493708 | chr5:39316131 | ENST00000263408 | 4 | 11 | 335_354 | 205 | 560.0 | Transmembrane | Beta stranded |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | LIFR | chr5:38493708 | chr5:39316131 | ENST00000263409 | - | 14 | 20 | 627_719 | 688 | 1098.0 | Domain | Fibronectin type-III 5 |
Hgene | LIFR | chr5:38493708 | chr5:39316131 | ENST00000263409 | - | 14 | 20 | 724_833 | 688 | 1098.0 | Domain | Fibronectin type-III 6 |
Hgene | LIFR | chr5:38493708 | chr5:39316131 | ENST00000453190 | - | 14 | 20 | 627_719 | 688 | 1098.0 | Domain | Fibronectin type-III 5 |
Hgene | LIFR | chr5:38493708 | chr5:39316131 | ENST00000453190 | - | 14 | 20 | 724_833 | 688 | 1098.0 | Domain | Fibronectin type-III 6 |
Hgene | LIFR | chr5:38493708 | chr5:39316131 | ENST00000263409 | - | 14 | 20 | 869_877 | 688 | 1098.0 | Motif | Note=Box 1 motif |
Hgene | LIFR | chr5:38493708 | chr5:39316131 | ENST00000453190 | - | 14 | 20 | 869_877 | 688 | 1098.0 | Motif | Note=Box 1 motif |
Hgene | LIFR | chr5:38493708 | chr5:39316131 | ENST00000263409 | - | 14 | 20 | 45_833 | 688 | 1098.0 | Topological domain | Extracellular |
Hgene | LIFR | chr5:38493708 | chr5:39316131 | ENST00000263409 | - | 14 | 20 | 859_1097 | 688 | 1098.0 | Topological domain | Cytoplasmic |
Hgene | LIFR | chr5:38493708 | chr5:39316131 | ENST00000453190 | - | 14 | 20 | 45_833 | 688 | 1098.0 | Topological domain | Extracellular |
Hgene | LIFR | chr5:38493708 | chr5:39316131 | ENST00000453190 | - | 14 | 20 | 859_1097 | 688 | 1098.0 | Topological domain | Cytoplasmic |
Hgene | LIFR | chr5:38493708 | chr5:39316131 | ENST00000263409 | - | 14 | 20 | 834_858 | 688 | 1098.0 | Transmembrane | Helical |
Hgene | LIFR | chr5:38493708 | chr5:39316131 | ENST00000453190 | - | 14 | 20 | 834_858 | 688 | 1098.0 | Transmembrane | Helical |
Tgene | C9 | chr5:38493708 | chr5:39316131 | ENST00000263408 | 4 | 11 | 138_509 | 205 | 560.0 | Domain | MACPF | |
Tgene | C9 | chr5:38493708 | chr5:39316131 | ENST00000263408 | 4 | 11 | 42_95 | 205 | 560.0 | Domain | TSP type-1 | |
Tgene | C9 | chr5:38493708 | chr5:39316131 | ENST00000263408 | 4 | 11 | 99_136 | 205 | 560.0 | Domain | LDL-receptor class A |
Top |
Fusion Gene Sequence for LIFR-C9 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>44655_44655_1_LIFR-C9_LIFR_chr5_38493708_ENST00000263409_C9_chr5_39316131_ENST00000263408_length(transcript)=4230nt_BP=2228nt AATCCTAACCCTCTCTCCCAGAACGTGTCTCTGCTGCAAGGCACCGGGCCCTTTCGCTCTGCAGAACTGCACTTGCAAGACCATTATCAA CTCCTAATCCCAGCTCAGAAAGGGAGCCTCTGCGACTCATTCATCGCCCTCCAGGACTGACTGCATTGCACAGATGATGGATATTTACGT ATGTTTGAAACGACCATCCTGGATGGTGGACAATAAAAGAATGAGGACTGCTTCAAATTTCCAGTGGCTGTTATCAACATTTATTCTTCT ATATCTAATGAATCAAGTAAATAGCCAGAAAAAGGGGGCTCCTCATGATTTGAAGTGTGTAACTAACAATTTGCAAGTGTGGAACTGTTC TTGGAAAGCACCCTCTGGAACAGGCCGTGGTACTGATTATGAAGTTTGCATTGAAAACAGGTCCCGTTCTTGTTATCAGTTGGAGAAAAC CAGTATTAAAATTCCAGCTCTTTCACATGGTGATTATGAAATAACAATAAATTCTCTACATGATTTTGGAAGTTCTACAAGTAAATTCAC ACTAAATGAACAAAACGTTTCCTTAATTCCAGATACTCCAGAGATCTTGAATTTGTCTGCTGATTTCTCAACCTCTACATTATACCTAAA GTGGAACGACAGGGGTTCAGTTTTTCCACACCGCTCAAATGTTATCTGGGAAATTAAAGTTCTACGTAAAGAGAGTATGGAGCTCGTAAA ATTAGTGACCCACAACACAACTCTGAATGGCAAAGATACACTTCATCACTGGAGTTGGGCCTCAGATATGCCCTTGGAATGTGCCATTCA TTTTGTGGAAATTAGATGCTACATTGACAATCTTCATTTTTCTGGTCTCGAAGAGTGGAGTGACTGGAGCCCTGTGAAGAACATTTCTTG GATACCTGATTCTCAGACTAAGGTTTTTCCTCAAGATAAAGTGATACTTGTAGGCTCAGACATAACATTTTGTTGTGTGAGTCAAGAAAA AGTGTTATCAGCACTGATTGGCCATACAAACTGCCCCTTGATCCATCTTGATGGGGAAAATGTTGCAATCAAGATTCGTAATATTTCTGT TTCTGCAAGTAGTGGAACAAATGTAGTTTTTACAACCGAAGATAACATATTTGGAACCGTTATTTTTGCTGGATATCCACCAGATACTCC TCAACAACTGAATTGTGAGACACATGATTTAAAAGAAATTATATGTAGTTGGAATCCAGGAAGGGTGACAGCGTTGGTGGGCCCACGTGC TACAAGCTACACTTTAGTTGAAAGTTTTTCAGGAAAATATGTTAGACTTAAAAGAGCTGAAGCACCTACAAACGAAAGCTATCAATTATT ATTTCAAATGCTTCCAAATCAAGAAATATATAATTTTACTTTGAATGCTCACAATCCGCTGGGTCGATCACAATCAACAATTTTAGTTAA TATAACTGAAAAAGTTTATCCCCATACTCCTACTTCATTCAAAGTGAAGGATATTAATTCAACAGCTGTTAAACTTTCTTGGCATTTACC AGGCAACTTTGCAAAGATTAATTTTTTATGTGAAATTGAAATTAAGAAATCTAATTCAGTACAAGAGCAGCGGAATGTCACAATCAAAGG AGTAGAAAATTCAAGTTATCTTGTTGCTCTGGACAAGTTAAATCCATACACTCTATATACTTTTCGGATTCGTTGTTCTACTGAAACTTT CTGGAAATGGAGCAAATGGAGCAATAAAAAACAACATTTAACAACAGAAGCCAGTCCTTCAAAGGGGCCTGATACTTGGAGAGAGTGGAG TTCTGATGGAAAAAATTTAATAATCTATTGGAAGCCTTTACCCATTAATGAAGCTAATGGAAAAATACTTTCCTACAATGTATCGTGTTC ATCAGATGAGGAAACACAGTCCCTTTCTGAAATCCCTGATCCTCAGCACAAAGCAGAGATACGACTTGATAAGAATGACTACATCATCAG CGTAGTGGCTAAAAATTCTGTGGGCTCATCACCACCTTCCAAAATAGCGAGTATGGAAATTCCAAATGATGATCTCAAAATAGAACAAGT TGTTGGGATGGGAAAGGGGATTCTCCTCACCTGGCATTACGACCCCAACATGACTTGCGACTACGTCATTAAGTGGTGTAACTCGTCTCG GTCGGAACCATGCCTTATGGACTGGAGAAAAGTTCCCTCAAACAGCACTGAAACTGTAATAGAATCTGACCAAAGGCGAGAAAAATTTCA GAACCGAACATTACGAAGAACAAATTGAAGCATTTAAAAGTATCATCCAAGAGAAGACATCAAATTTTAATGCAGCTATATCTCTAAAAT TTACACCCACTGAAACAAATAAAGCTGAACAATGTTGTGAGGAAACAGCCTCCTCAATTTCTTTACATGGCAAGGGTAGTTTTCGGTTTT CATATTCCAAAAATGAAACTTACCAACTATTTTTGTCATATTCTTCAAAGAAGGAAAAAATGTTTCTGCATGTGAAAGGAGAAATTCATC TGGGAAGATTTGTAATGAGAAATCGCGATGTTGTGCTCACAACAACTTTTGTGGATGATATAAAAGCTTTGCCAACTACCTATGAAAAGG GAGAATATTTTGCCTTTTTGGAAACCTATGGAACTCACTACAGTAGCTCTGGGTCTCTAGGAGGACTCTATGAACTAATATATGTTTTGG ATAAAGCTTCCATGAAGCGGAAAGGTGTTGAACTAAAAGACATAAAGAGATGCCTTGGGTATCATCTGGATGTATCTCTGGCTTTCTCTG AAATCTCTGTTGGAGCTGAATTTAATAAAGATGATTGTGTAAAGAGGGGAGAGGGTAGAGCTGTAAACATCACCAGTGAAAACCTCATAG ATGATGTTGTTTCACTCATAAGAGGTGGAACCAGAAAATATGCATTTGAACTGAAAGAAAAGCTTCTCCGAGGAACCGTGATTGATGTGA CTGACTTTGTCAACTGGGCCTCTTCCATAAATGATGCTCCTGTTCTCATTAGTCAAAAACTGTCTCCTATATATAATCTGGTTCCAGTGA AAATGAAAAATGCACACCTAAAGAAACAAAACTTGGAAAGAGCCATTGAAGACTATATCAATGAATTTAGTGTAAGAAAATGCCACACAT GCCAAAATGGAGGTACAGTGATTCTAATGGATGGAAAGTGTTTGTGTGCCTGCCCATTCAAATTTGAGGGAATTGCCTGTGAAATCAGTA AACAAAAAATTTCTGAAGGATTGCCAGCCCTAGAGTTCCCCAATGAAAAATAGAGCTGTTGGCTTCTCTGAGCTCCAGTGGAAGAAGAAA ACACTAGTACCTTCAGATCCTACCCCTGAAGATAATCTTAGCTGCCAAGTAAATAGCAACATGCTTCATGAAAATCCTACCAACCTCTGA AGTCTCTTCTCTCTTAGGTCTATAATTTTTTTTTAAATTTTTCTTCCTTAAACTCCTGTGATGTTTCCATTTTTTGTTCCCTAATGAGAA GTCAACAGTGAAATACGCCAGAACTGCTTTATCCCACGGAAAATGCCAATCTCTTCTAAAAAAAAACAAAATTAAATTAAAAACAGAATG TTGGTTTAAAAAACTTCAAAGTAATTTTCAAACGGCTTTGTATGGTTAACATATTCTGCCAGGTCCATGACCACACGTCTGTACCATGCA ATTTAACTCTTATTTACATTGTTATGTTTAGTTTGGTTATTTGCTTAGGTGTGCATACATTCATTCAGCAAATGCTGAGCACCAGCCACG TGCACAGCAGTTGCTTTTACTAGTCTTAGCTCTACGATTTAAATCCATGTGTCCAAGGGGGAAAACATATTATATTTGTAACCAAAAACT ACTAGTTTACCAGAGGACTGAAGGGAGATAAAGAGGAGTTGGTTAATGGGTACAAAAATCCAGTTAGATGAAAGGAATAATATAGATAGT GTTCAGTAGCAGAATAGAATGAACATAAACTATTAGTTTAAATTATGTGAAATTCCTTCTATTTGATCATATTTTACAAGAAAAAACATC AATTTTATATAGTCCAACTTAATACCTAGCCTTATGAGTTGTATAAGGTAAGGTTACCTACCTGAGAAGCTGATTAACATTGGTTGTACA ATCTTATTCATTAGAGAACATGGTGCTTAGGGTCTGAGACCTTTTGAAAGGTCTGAGAACTCTTTAAAAAAAGGAAAGAAAGAAAGAAAA >44655_44655_1_LIFR-C9_LIFR_chr5_38493708_ENST00000263409_C9_chr5_39316131_ENST00000263408_length(amino acids)=704AA_BP=688 MMDIYVCLKRPSWMVDNKRMRTASNFQWLLSTFILLYLMNQVNSQKKGAPHDLKCVTNNLQVWNCSWKAPSGTGRGTDYEVCIENRSRSC YQLEKTSIKIPALSHGDYEITINSLHDFGSSTSKFTLNEQNVSLIPDTPEILNLSADFSTSTLYLKWNDRGSVFPHRSNVIWEIKVLRKE SMELVKLVTHNTTLNGKDTLHHWSWASDMPLECAIHFVEIRCYIDNLHFSGLEEWSDWSPVKNISWIPDSQTKVFPQDKVILVGSDITFC CVSQEKVLSALIGHTNCPLIHLDGENVAIKIRNISVSASSGTNVVFTTEDNIFGTVIFAGYPPDTPQQLNCETHDLKEIICSWNPGRVTA LVGPRATSYTLVESFSGKYVRLKRAEAPTNESYQLLFQMLPNQEIYNFTLNAHNPLGRSQSTILVNITEKVYPHTPTSFKVKDINSTAVK LSWHLPGNFAKINFLCEIEIKKSNSVQEQRNVTIKGVENSSYLVALDKLNPYTLYTFRIRCSTETFWKWSKWSNKKQHLTTEASPSKGPD TWREWSSDGKNLIIYWKPLPINEANGKILSYNVSCSSDEETQSLSEIPDPQHKAEIRLDKNDYIISVVAKNSVGSSPPSKIASMEIPNDD -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for LIFR-C9 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for LIFR-C9 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Tgene | C9 | P02748 | DB09130 | Copper | Small molecule | Approved|Investigational |
Top |
Related Diseases for LIFR-C9 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | LIFR | C0796176 | STUVE-WIEDEMANN SYNDROME | 3 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
Hgene | LIFR | C0032460 | Polycystic Ovary Syndrome | 1 | CTD_human |
Hgene | LIFR | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
Hgene | LIFR | C0036341 | Schizophrenia | 1 | PSYGENET |
Hgene | LIFR | C0349398 | Paranoid delusion | 1 | PSYGENET |
Hgene | LIFR | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human |
Hgene | LIFR | C0432240 | Stuve-Wiedemann dysplasia | 1 | ORPHANET |
Hgene | LIFR | C1136382 | Sclerocystic Ovaries | 1 | CTD_human |
Hgene | LIFR | C1968949 | Cakut | 1 | GENOMICS_ENGLAND |
Hgene | LIFR | C2239176 | Liver carcinoma | 1 | CTD_human |
Tgene | C0003257 | Antibody Deficiency Syndrome | 2 | CTD_human | |
Tgene | C0021051 | Immunologic Deficiency Syndromes | 2 | CTD_human | |
Tgene | C2239176 | Liver carcinoma | 2 | CTD_human | |
Tgene | C3151189 | C9 Deficiency | 2 | CTD_human;GENOMICS_ENGLAND;UNIPROT | |
Tgene | C0011633 | Dermatomyositis | 1 | CTD_human | |
Tgene | C0015456 | Facial Dermatoses | 1 | CTD_human | |
Tgene | C0015704 | Favre-Racouchot Syndrome | 1 | CTD_human | |
Tgene | C0025294 | Meningococcal meningitis | 1 | CTD_human | |
Tgene | C0027412 | Opioid-Related Disorders | 1 | CTD_human | |
Tgene | C0029095 | Opioid abuse | 1 | CTD_human | |
Tgene | C0041834 | Erythema | 1 | CTD_human | |
Tgene | C0221056 | Adult type dermatomyositis | 1 | CTD_human | |
Tgene | C0242383 | Age related macular degeneration | 1 | CTD_human | |
Tgene | C0263666 | Dermatomyositis, Childhood Type | 1 | CTD_human | |
Tgene | C0272242 | Complement deficiency disease | 1 | GENOMICS_ENGLAND | |
Tgene | C0343097 | Nodular Elastoidosis | 1 | CTD_human | |
Tgene | C0345967 | Malignant mesothelioma | 1 | CTD_human | |
Tgene | C0524661 | Narcotic Abuse | 1 | CTD_human | |
Tgene | C0524662 | Opiate Addiction | 1 | CTD_human | |
Tgene | C1135745 | Meningitis, Meningococcal, Serogroup A | 1 | CTD_human | |
Tgene | C1135746 | Meningitis, Meningococcal, Serogroup B | 1 | CTD_human | |
Tgene | C1135747 | Meningitis, Meningococcal, Serogroup C | 1 | CTD_human | |
Tgene | C1136209 | Meningitis, Meningococcal, Serogroup Y | 1 | CTD_human | |
Tgene | C1136210 | Meningitis, Meningococcal, Serogroup W-135 | 1 | CTD_human | |
Tgene | C1527402 | Narcotic Dependence | 1 | CTD_human | |
Tgene | C3810042 | MACULAR DEGENERATION, AGE-RELATED, 15 | 1 | CTD_human;UNIPROT | |
Tgene | C4551628 | Opiate Abuse | 1 | CTD_human |